

LIST OF FIGURES

Figure 1: Etiopathological factors of hypertension.....	9
Figure 2: Different physiological mechanisms to prevent rise in abnormal blood pressure. These mechanisms operate through the brain, vasculature and kidneys.....	11
Figure 3: Remodeling may be hypertrophic (increased cross-sectional area as observed in severe hypertension), eutrophic (no change in cross-sectional area, mild-to-moderate hypertension) or hypotrophic (decreased cross-sectional area, following chronic antihypertensive therapy).....	15
Figure 4: The complete renin-angiotensin cascade	20
Figure 5: Resiniferatoxin (RTX) is a plant alkaloid obtained from the plant <i>Euphorbia resinifera</i> . It is an ultrapotent analog of capsaicin and activator of TRPV1. It is an important pharmacological tool to study the effects of TRPV1 activation <i>in vivo</i>	26
Figure 6: The physiology of renalase and its effect on catecholamine regulation.....	27
Figure 7: Concentration response curves of phenylephrine in presence and absence of prazosin.....	54
Figure 8: Concentration response curves to angiotensin II in presence and absence of losartan.....	54
Figure 9: Concentration response curves of angiotensin II against, A) prazosin (80pM), B) doxazosin (10µM) and C) terazosin (10µM).....	57
Figure 10: Concentration response curves of phenylephrine against, A) losartan (10µM), B) valsartan (10µM) and C) olmesartan (10µM).....	58
Figure 11: This figure represents the six series of compounds that were chosen as part of the preliminary screening protocol to identify a potential dual antagonist. 6, 7-Dimethoxyquinazoline ring system is native to all the series with series I-III being 4-keto derivatives and series IV-VI being 4-amino derivatives. Other differences are observed at the substitutions on 2 nd and 3 rd positions.....	59
Figure 12: Concentration response curves to phenylephrine (A) and angiotensin II (B) in presence of different concentrations of MCR-1329 (0, 1, 5, 10 µM).....	63
Figure 13: Mean arterial pressor response inhibition of phenylephrine (A) and angiotensin II (B) in animals previously dosed with MCR-1329 or standards at equimolar levels (prazosin for phenylephrine and losartan for angiotensin II).....	65

Figure 14: Mean arterial pressor responses to phenylephrine under losartan masking (checkerd columns)and to ang II under prazosin masking (ruled columns). In case of phenylephrine challenge, the effect of MCR-1329 was found to be moderate in comparison to prazosin.....	67
Figure 15: Mean arterial pressor responses to phenylephrine under losartan masking (checkered columes) and to ang II under terazosin masking (ruled columns). In case of phenylephrine challenge, the effect of MCR-1329 was found to be statistically comparable without any significant difference.....	68
Figure 16: Chromatogram showing an overlay of peaks for calibration curve of analytical aliquots of the MCR-1329. The abscissa represents time in mins while the ordinate represents peak intensity in microvolts.....	73
Figure 17: Calibration curve of MCR-1329 from analytical samples dissolved in mobile phase. This graph was plotted using mean peak areas obtained for each peak at different concentrations.....	74
Figure 18: Chromatogram showing an overlay of peaks for calibration curve of spiked plasma samples. The abscissa represents time in mins while the ordinate represents peak intensity in microvolts.....	74
Figure 19: Calibration curve of MCR-1329 from spiked plasma samples. This graph was plotted using mean peak areas obtained for each peak at different concentrations.....	75
Figure 20: The figure shows the plasma concentration v/s time profile of MCR-1329 after oral administration to rats (10mg/kg, n=6).....	76
Figure 21: Time course of release of MCR-1329 from human plasma protein binding. It is important to note that even after 24 hrs more than 40% MCR-1329 remained bound to the plasma proteins and the slope of the curve is reduced after about 8 hrs.....	78
Figure 22: Figure shows the effects of mineralocorticoid induced hypertension in different groups of animals before and after induction/treatment. The figure clearly shows that all the groups are normotensive in the pre-induction phase whereas severe hypertension is evident in the UNX-DOCA salt group. The animals treated with MCR-1329 or a combination of prazosin and losartan were able to prevent DOCA-salt mediated hypertension in the animals.....	80
Figure 23: The columns indicate mean arterial pressures from different animals recorded at the carotid artery. It is evident from the graph that UNX-DOCA salt animals were severely hypertensive at the terminal stage of the study. Treatment with MCR-1329 was able to ablate these destructive effects of DOCA salt and was comparable to those of standards.....	80

Figure 24: Figure demonstrates the ratio of kidney:body weight in different groups of animals. It is evident from the figure that UNX <i>per se</i> does not lead to kidney hypertrophy but additional overload produced by DOCA-salt causes the kidney to increase in size to compensate for GFR and other renal activities.....	81
Figure 25: Effect of MCR-1329 in UNX-DOCA salt hypertension. The figure summarizes the effect of MCR-1329 on urinary indices.....	84
Figure 26: Cumulative concentration response curves to Ach (10^{-9} – 10^{-5} M) in endothelium-intact strips precontracted with phenylephrine (1.5×10^{-6} M) from all the groups (n=3).....	85
Figure 27: Uric acid levels in the serum of UNX, UNX-DOCA salt and MCR-1329 were found to be comparable (n=5).....	86
Figure 28: Light micrographs representing renal histology of different groups (Periodic acid Schiff stain, 40X, bars represent 10µm).....	89
Figure 29: Survival of cells post-incubation with different concentrations of MCR-1329, vehicle and control cells are shown (n=6).....	90
Figure 30: This figure indicates the controls in the flow cytometry experiment. Unstained cells shown no deviation from the parent population (A) and treatment with only 2° antibody did not show any major shift towards the P3 population (B) suggesting that washing efficiency and dilutions are optimal.....	91
Figure 31: The scatter obtained from flow cytometry and corresponding histograms are shown here. P1 is the entire population gated from 10000 events.....	92
Figure 32: The scatter obtained from flow cytometry and corresponding histograms are shown here. P1 is the entire population gated from 10000 events.....	93

TABLE OF CONTENTS

Table 1: Classification of hypertension based on different national guidelines.....	6
Table 2: Oral antihypertensive drugs.....	23
Table 3: IUPHAR data for the different alpha1-adrenergic receptor subtypes.....	35
Table 4: Novel fixed dose combinations being investigated for arterial hypertension.....	46
Table 5: Preliminary studies on compounds of series I.....	59
Table 6: Preliminary studies on compounds of series II.....	60
Table 7: Preliminary studies on compounds of series III.....	60
Table 8: Preliminary studies on compounds of series IV.....	61
Table 9: Preliminary studies on compounds of series V.....	61
Table 10: Preliminary studies on compounds of series VI.....	62
Table 11: Absorbance of MCR-1329 at different wavelengths.....	70
Table 12: Mobile phase combinations evaluated for elution of MCR-1329.....	71
Table 13: Optimized HPLC parameters for quantification of MCR-1329.....	72
Table 14: Intra-day and inter-day precision of the method and recovery data.....	75
Table 15: Summary of pharmacokinetic data based on non-compartmental model.....	77
Table 16: Quantitative summary of flow cytometry data.....	94
Table 17: Parameter evaluation detail in the DOCA model.....	102
Table 18: Treatment indications for cell signaling studies.....	106

LIST OF FIGURES

Figure 1: The classical reaction catalysed by ACAT.....	149
Figure 2: Physiological functions of ACAT.....	156
Figure 3: Trends of publication on ACAT.....	166
Figure 4: A typical chromatogram of cholesteryl oleate.....	181
Figure 5: A typical regression curve obtained for standard and test samples of cholesteryl oleate. Coefficient of correlation closely approaches unity and quantity of cholesteryl oleate in the test samples also falls on the linearity curve.....	181
Figure 6: An overlay of the peaks obtained from standard and samples of cholesteryl oleate. This figure shows that the relative retention of standard cholesteryl oleate and from analyte samples remains the same. It may also be observed that no interference could be found in the analyte detection range.....	182
Figure 7: No peaks were found at the sample R _f when blank matrix was utilized for spotting.....	183
Figure 8: A plot showing the relation between total cholesterol and cholesteryl esters from plasma samples of 3 patients having total cholesterol levels higher than 200 mg/dl. Cholesteryl esters are expressed as a function of cholesteryl oleate. Results are expressed as a mean of triplicate analysis.....	187
Figure 9: effects of P-407 on 24 hr triglyceride turnover measured as fold-change in TG at 0 hr and 24 hr after administration of P-407.....	194
Figure 10: Figure shows mean body weight of all the groups before and after treatment. It may be noted that no significant change was observed between any groups towards the end of the study.....	198
Figure 11: Figure represent the lipid profile of all the groups at the initial and terminal phases of study.....	200
Figure 12: This figure shows representative aortae from each group.....	201
Figure 13: Fatty streaks observed by <i>en face</i> lipid staining were analysed by the ImageJ image analysis software and the lesion areas (stained maroon) were calculated respective to the total aortic strip area.....	202
Figure 14: This figure represents the cross-sectional areas from aortic roots after sacrificing animals of the different groups.....	203
Figure 15: Protocol for diet administration, sampling and tissue collection in the atherogenic diet model.....	211

LIST OF TABLES

Table 1: Significant events in the history of ACAT.....	151
Table 2: Potential ACAT substrates.....	160
Table 3: Different mobile phase systems for resolution of cholesteryl oleate.....	179
Table 4: Linear regression data of calibration curves.....	184
Table 5: Precision and Recovery.....	184
Table 6: Robustness of the method.....	185
Table 7: Validation using plasma samples.....	185
Table 8: Preliminary screening of compounds from series I.....	188
Table 9: Preliminary screening of compounds from series II.....	189
Table 10: Preliminary screening of compounds from series III.....	189
Table 11: Preliminary screening of compounds from series IV.....	190
Table 12: Preliminary screening of compounds from series V.....	191
Table 13: Determination of IC ₅₀ on ACAT for selected compounds.....	192
Table 14: List of materials and their source for the atherogenic-diet model.....	210
Table 15: Protocol for total cholesterol estimation.....	212
Table 16: Protocol for triglyceride estimation.....	213
Table 17: Sample preparation for HDL-cholesterol estimation.....	214
Table 18: Protocol for HDL-cholesterol estimation.....	214